CompletedNCT06880328

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

Medication studyAges 18–50United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations: Glendale and 3 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateStarted: November 7, 2018

Recruitment status: Completed
Enrollment listed in the registry: 35
Sponsor: Hoffmann-La Roche
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 50 Years
Official registry ID: NCT06880328
Official title: Show the full official title
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET), Randomized, Double-blind, Crossover Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With 150mg of RO6889450 or Placebo in Patients With Schizophrenia

Completed

Glendale · Torrance · Gaithersburg

1 more locations

FAQ

Who is behind this study?

The study sponsor is Hoffmann-La Roche.

Did this study involve medication?

Yes. The study involved medication, including Ralmitaront and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.